Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: tumour-specific immunotherapies - Metaclipse Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: tumour-specific immunotherapies - Metaclipse Therapeutics

Alternative Names: MembrexTM immunotherapy; MembrexTM-based tumour-specific immunotherapy; TMV vaccine - Metaclipse Therapeutics; Tumor membrane-based vaccines - Metaclipse Therapeutics; Tumor tissue-based vaccine - Metaclipse Therapeutics; Tumor vaccine - Metaclipse Therapeutics

Latest Information Update: 17 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metaclipse Therapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Head and neck cancer; Triple negative breast cancer
  • No development reported Lymphoma; Malignant melanoma; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 31 May 2024 Pharmacodynamics and immunogenicity data from the preclinical studies presented at 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 12 Apr 2024 Preclinical development in Head-and-neck-cancer and Triple-negative-breast-cancer is ongoing in USA (Parenteral)
  • 12 Apr 2024 Metaclipse in collaboration with Syntekabio plans a phase I/II trial for Triple negative breast cancer in 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top